Business
Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting
MELBOURNE, Australia and SAN FRANCISCO, April 03, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that an oral presentation and a poster presentation related to Alterity’s clinical programs in Multiple System Atrophy (MSA) will be delivered at the American Academy of Neurology (AAN) 2025 Annual Meeting taking place Apr
About this update from Alterity Therapeutics Ltd.
[{"type":"image","alt":"ALTERITY THERAPEUTICS LIMITED","displaySize":"","headline":null,"caption":"ALTERITY THERAPEUTICS LIMITED","className":"","disableSlideshowImg":false,"size":{"original":{"width":222,"height":56,"url":"https://media.zenfs.com/en/globenewswire.com/5761c8df20b76a3904e54a7775315c62"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/aH_lC7vKS4YC2ZvHbgCTDQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5761c8df20b76a3904e54a7775315c62","width":222,"height":56}},"lazy":false},{"type":"text","content":"MELBOURNE, Australia and SAN FRANCISCO, April 03, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that an oral presentation and a poster presentation related to Alterity’s clinical programs in Multiple System Atrophy (MSA) will be delivered at the American Academy of Neurology (AAN) 2025 Annual Meeting taking place April 5 - 9, 2025 in San Diego, CA.","length":532,"tagName":"p"},{"type":"text","content":"David Stamler, M.D., Chief Executive Officer of Alterity, commented, “We are excited to present the positive topline data along with new analyses from our ATH434-201 clinical trial via an oral presentation at AAN, one of the premier global neurology meetings. In addition, data will be presented on the use of wearable sensor technology to assess patient outcomes, an important component of evaluating novel treatments for individuals with MSA.”","length":445,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"style":"max-width:15%;width:15%;min-width:15%;text-align:justify;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"Type: ","length":5,"tagName":"p","attribs":{}}]},{"style":"max-width:85%;width:85%;min-width:85%;text-align:justify;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"Oral Presentation","length":17,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"text-align:justify;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"Title: ","length":6,"tagName":"p","attribs":{}}]},{"style":"text-align:justify;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"Topline Data from a Randomized, Double Blin...